A 50-year-old man was referred to the Advanced Heart Failure clinic at our institution for consideration of additional treatment options. He was diagnosed with heart failure (HF) 4 years earlier. Transthoracic echocardiography revealed a dilated left ventricle (LV) with an LV end-diastolic dimension of 5.5 cm, globally depressed ejection fraction (EF; estimated at 30%), and moderate mitral regurgitation. Complete blood cell count, urinalysis, and liver function tests were normal. Screening for hemochromatosis, human immunodeficiency virus, rheumatologic disease, and amyloidosis was performed and was negative. He did not have a family history of cardiomyopathy or sudden cardiac death. Coronary angiography revealed no evidence of obstructive coronary artery disease. Right heart catheterization demonstrated a right atrial pressure of 15 mm Hg, pulmonary artery pressure of 41/21 mm Hg, pulmonary capillary wedge pressure of 20 mm Hg, and cardiac index of 2.3 L ⅐ min ؊1 ⅐ m ؊2 . He was started on evidence-based therapies for HF. An implantable cardioverter-defibrillator was placed for primary prevention of sudden cardiac death after no improvement in his EF. He was not considered a candidate for cardiac resynchronization therapy because his QRS duration was 100 milliseconds. He had progressive HF symptoms despite maximal medical therapy and was hospitalized 3 times during the 6 months before referral for acute decompensated HF. The doses of angiotensin-converting enzyme inhibitor and ␤-blocker had been recently reduced by his cardiologist secondary to lightheadedness and fatigue accompanied by hypotension. His medical history was remarkable for hypertension and dyslipidemia. He reported adherence to his prescribed medications that included carvedilol 6.25 mg twice daily, lisinopril 5 mg daily, spironolactone 25 mg daily, and furosemide 40 mg daily.
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Dr Rogers:
It is timely to refer this patient for advanced HF therapies because these therapies improve functional status and long-term prognosis of patients with refractory HF. 1 Referral is appropriate not only for potential heart transplantation or mechanical circulatory support (MCS) but also for medical management of persistent functional class III and IV symptoms. 2 The clinical history suggests that this patient has an idiopathic nonischemic cardiomyopathy with persistent symptomatic HF. He has been treated with angiotensinconverting enzyme inhibitors and ␤-blockers, therapies that form the cornerstone of treatment to delay or halt the progression of cardiac dysfunction and improve mortality. Aldosterone antagonists are also recommended for patients with New York Heart Association class III to IV HF secondary to reduced LVEF (Ͻ35%). Diuretic therapy, although not associated with improvement in outcomes, is recommended to restore and maintain normal volume status. 3 In this case, the history of frequent hospitalizations and reductions in neurohormonal antagonists doses for hypotension are markers of poor prognosis and suggest that the illness is progressing despite optimal medical therapy. 4, 5 The predicted 1-year survival of this patient may be nearly 70% by some risk prediction models, but these models may underestimate incremental risk from recurrent hospitalizations, medication changes, and ventricular arrhythmias in the setting of preserved end-organ function. 6 Additionally, these models perform modestly in predicting outcomes and overestimate survival free of ventricular assist device (VAD) or urgent transplantation in advanced HF. 7 Estimating and communicating the short-to intermediate-term risk of death without advanced therapies is an important feature of patient management. The physical examination should be directed toward determination of cardiac filling pressures and the presence of ventricular enlargement, pulmonary hypertension, valvular heart disease, and reduced cardiac output. It is also important to perform objective assessments of cardiac function via 2-dimensional echocardiography with Doppler to assess LVEF, LV size, wall thickness, and valve function.
On physical examination, his temperature was 98.6°F, blood pressure was 90/70 mm Hg, pulse was 110 bpm, and oxygen saturation on room air was 98%. His body mass index was 19 kg/m 2 . In general, he appeared lethargic and cachectic. Sclerae were anicteric and his oral mucosa was moist. There was no thyromegaly. Lung fields were clear. Cardiac examination revealed depressed carotid upstrokes; the jugular venous pressure was estimated at 8 cm of H 2 0 without hepatojugular reflux. He had a square wave response to the Valsalva maneuver. The apical impulse was in the anterior axillary line. There was a regular rhythm with a normal first and second heart sound without an S3; a III/VI holosystolic murmur was heard at the apex that radiated to the axilla. His abdomen was soft and nondistended with active bowel sounds. There was no hepatosplenomegaly. His extremities were cool and without edema. Laboratory data were significant for sodium of 129 mmol/L, creatinine of 1.5 mg/dL, normal thyroid and liver function tests, and hemoglobin of 10.3 g/dL. An ECG revealed normal sinus rhythm with a left anterior fascicular block and QRS duration of 110 milliseconds. An echocardiogram demonstrated severe global LV dysfunction with an estimated LVEF of <15% and LV end-diastolic dimension of 8 cm; his right ventricular (RV) function was normal. There was mild tricuspid and moderate mitral regurgitation.
A careful physical examination yields key information in the evaluation of patients with HF. In this case, the patient appeared lethargic and had hypotension, a narrow pulse pressure, and cool extremities, all signs of a low cardiac output state. The proportional pulse pressure [(systolicϪdia-stolic)/systolic)] of 22% suggests a cardiac index Ͻ2.2 L ⅐ min Ϫ1 ⅐ m Ϫ2 . 8 Additionally, these patients often have increased adrenergic tone, which can result in tachycardia, pallor, and cool extremities. His arterial pulse should be evaluated for pulsus alternans, which is characteristic of advanced HF. Assessment of the jugular venous pressure should be performed carefully; in this patient, it was not elevated and there was no hepatojugular reflux, indicating that right-sided cardiac pressures were normal or low. The cardiovascular response to the Valsalva maneuver is a simple, inexpensive, and highly sensitive bedside test for estimation of volume status and detection of LV systolic dysfunction in patients with HF. With the blood pressure cuff inflated 15 mm Hg over the systolic pressure, the patient is asked to perform a Valsalva maneuver. A normal response is when Korotkoff sounds are audible only at the onset of straining and at release. In patients with HF, Korotkoff sounds can be heard throughout the Valsalva maneuver (the square wave response) or a lack of reappearance of the sounds after release (the absent overshoot response). 9 The third heart sound (or gallop rhythm) is commonly present with tachycardia and volume overload and signifies severe hemodynamic compromise and elevated left-sided filling pressures. 10 The laterally displaced apical impulse is indicative of LV enlargement. This patient has a murmur of mitral regurgitation, although severe regurgitation can be present in the absence of an audible murmur. It is important to remember that signs of pulmonary congestion such as rales and pulmonary edema may be lacking in patients with chronic HF and elevated PCWPs. Despite the lack of abdominal complaints, examination should be performed to determine the presence of ascites, hepatosplenomegaly, or a pulsatile liver. It is not uncommon for patients with advanced HF to present with severe right upper quadrant pain and to undergo cholecystectomy when the actual culprit is acute hepatic congestion. Finally, the finding of cachexia in patients with end-stage HF is associated with a particularly poor prognosis. Although the mechanisms are not entirely understood, elevated levels of circulating cytokines have been implicated. 11 Clues from the physical examination can also classify patients according to hemodynamic profiles based on evidence of congestion (eg, orthopnea, elevated jugular venous pressure, rales, edema) and perfusion (narrow pulse pressure, cool extremities, oliguria). 8, 12 Accurate assessment of these profiles guides therapeutics. This patient has signs of systemic hypoperfusion but appears to be euvolemic. Although a minority of patients admitted with HF have cardiogenic shock, this population requires rapid assessment and treatment with vasodilators (eg, nitroprusside), inotropic-vasodilator therapy (eg, milrinone, or dobutamine), or even temporary mechanical support (intra-aortic balloon pump [IABP] ). On the basis of the hemodynamic profile of this patient, he should be carefully evaluated for use of therapies that specifically augment cardiac output.
Laboratory evaluation reveals hyponatremia, which is a common problem in patients with HF, the severity of which is directly related to the extent of myocardial dysfunction, and is associated with adverse prognosis. 13 He also exhibits elevated serum creatinine, which may represent a prerenal state from reduced cardiac output, venous congestion, and intra-abdominal hypertension or excessive diuresis. 14 Anemia is also noted, which is associated with poor outcomes and is an emerging therapeutic target. 15 Transthoracic echocardiography remains the essential imaging modality for the evaluation of cardiac structure and function in these patients and allows measurement of adverse cardiac remodeling that occurs with progressive HF. Beyond LVEF, chamber size, RV function, and the presence of regurgitant valvular lesion are also important prognostic indicators. 16, 17 In this case, the patient has severely reduced LV function and an enlarged LV cavity; both are associated with a poor prognosis and provide objective evidence that this patient's progressive symptoms are due to worsening pump failure with limited chance for recovery with contemporary medical therapy.
Because of these findings, the patient was electively admitted for an inpatient evaluation for advanced HF therapies. He underwent right heart catheterization that revealed right atrial pressure of 7 mm Hg, pulmonary artery pressure of 40/19 mm Hg, and PCWP of 20 mm Hg. The cardiac index was 1.8 L ⅐ min ؊1 ⅐ m ؊2 and the pulmonary vascular resistance was 1.85 Wood units. Cardiopulmonary exercise testing was performed, during which the patient achieved a peak workload of 7 metabolic equivalents, a peak oxygen consumption (peak V O 2 ) of 13.0 mL ⅐ kg ؊1 ⅐ min ؊1 (32% of predicted), a V E/V co2 slope of 46, at a peak respiratory exchange ratio of 1.2. The patient was subsequently started on milrinone therapy at 0.25 g ⅐ kg؊1 ⅐ min؊1, and his carvedilol was discontinued. Repeat right heart catheterization revealed a right atrial pressure of 9 mm Hg, pulmonary artery pressure of 30/15 mm Hg (23), and PCWP of 15 mm Hg. The cardiac index had increased to 2.1 L ⅐ min؊1 ⅐ m؊2, and the pulmonary vascular resistance was 2.05 Wood units. He underwent evaluation for cardiac transplantation and was listed as a United Network for Organ Sharing status 1B candidate.
Hemodynamic evaluation revealed normal right and moderately elevated left-sided filling pressures and a low cardiac output. This hemodynamic profile is consistent with the patient's symptoms of fatigue without dyspnea or congestion at rest (PCWP, 15-20 mm Hg) and an inability to augment cardiac output with exertion (peak V O 2 , 13.0 mL ⅐ kg Ϫ1 ⅐ min Ϫ1 ). Additional diuresis and vasodilator therapy may not improve symptoms given the low right-sided filling pressures and systemic hypotension, respectively. 12 Thus, for immediate management of the patient's symptoms (particularly the lethargy), a treatment regimen that included the use of intravenous inotropic-vasodilator therapy seems reasonable.
Intravenous inotropic-vasodilator agents (dobutamine and milrinone) augment myocardial contractility and cardiac output, reduce afterload, and often are associated with clinical improvement. The choice between these agents typically reflects institutional experience but also whether the patient is able to tolerate further reductions in systemic blood pressure given the potent vasodilatory effects of milrinone. Concomitant use of ␤-blockers with long-term inotropic support has not been well studied. Competitive binding for the ␤-adrenergic receptor is likely when ␤-blockers are used with dobutamine, so we typically avoid this combination. The hemodynamic and clinical improvement with inotropes is often only transient and typically is followed by clinical decline, providing limited options for long-term therapy. Several recent studies have demonstrated that patients with HF severity of illness sufficient to require inotropes have mortality rates of nearly 80% at 2 years. 18, 19 Nevertheless, extended intravenous inotropic therapy is frequently used among patients with end-stage HF who are undergoing consideration for advanced therapies to reduce symptom burden and to decrease hospitalizations. In this case, it would be reasonable to initiate milrinone infusion to treat the symptoms associated with low cardiac output and to move toward listing for cardiac transplantation given his intermediate-term risk for death.
Cardiopulmonary exercise testing is a test of symptomlimited metabolic stress to calculate peak V O 2 , a potent predictor of outcome in ambulatory HF patients. Since the original description by Mancini et al 20 using cardiopulmonary exercise testing for risk stratification in patients with advanced HF, a peak V O 2 of Յ14 mL ⅐ kg Ϫ1 ⅐ min Ϫ1 has been used as a threshold for cardiac transplantation. In contemporary studies performed in an era of ␤-blocker therapy and cardiac resynchronization therapy, a lower threshold of 10 to 12 mL ⅐ kg Ϫ1 ⅐ min Ϫ1 has been suggested for consideration of advanced therapies. 1 Other cardiopulmonary exercise testing parameters such as V E/V CO 2 slope can further risk stratify patients into a high-risk category. 21 In fact, some studies have suggested that the V E/V CO 2 slope is a better predictor of outcome than peak V O 2 , LVEF, and New York Heart Association class. 21 An elevated V E/V CO 2 slope may be due to perfusion mismatching and an abnormally heightened chemosensitivity and ergoreflex response. This patient's peak V O 2 of 13.0 mL ⅐ kg Ϫ1 ⅐ min Ϫ1 , coupled with evidence of a V E/V CO 2 of 46, is indicative of a poor prognosis (Ͼ50% 2-year risk of adverse events), for which there is a clear benefit of advanced therapies over continued medical therapy. 21, 22 Over a short time, the patient's symptoms worsened. He was continually fatigued, was frequently lightheaded, and could not perform even basic activities of daily living. Three weeks after discharge on milrinone, he was rehospitalized for acute decompensated HF. Several attempts to augment his blood pressure with additional inotropic agents failed, and he demonstrated evidence of hypoperfusion, including obtundation, anuria, lactic acidosis, and hypoxic liver injury. Evaluation of invasive hemodynamics via a Swan-Ganz catheter revealed a PCWP of 35 mm Hg and a cardiac index of 1.5 L ⅐ min ؊1 ⅐ m
؊2
. A dopamine infusion was initiated and an IABP inserted, with overall improvement in hemodynamics and end-organ function.
Dr Rogers:
The patient now presents with critical cardiogenic shock in which systemic perfusion is unable to meet resting metabolic demands, and end-organ function is compromised. In cases such as this, rapid assessment and escalation of therapies are critical for survival. Hemodynamic support with pharmacological agents should be initiated rapidly with inotropic agents and vasopressors. The use of IABP is most validated in cardiogenic shock resulting from myocardial ischemia, but it remains a potentially lifesaving intervention in refractory pump failure from other causes that can be rapidly deployed while more definitive therapies are considered. At this juncture, it is critical to seek input from a cardiac surgeon for consideration of MCS or cardiac transplantation. Before proceeding with aggressive therapies, the patient and the family should be informed about prognosis, treatment options, and goals of care. 23 Dr Milano: While cardiac transplantation has been identified as the goal therapy in this patient, its use is frequently limited by donor organ shortage, unpredictable availability, and medical and/or social variables that determine recipient adequacy. Given the critical nature of the patient's current clinical status, it is appropriate at this juncture to consider short-term MCS to make a decision for transplant candidacy and to stabilize the patient until an appropriate organ becomes available.
The patient was listed as United Network for Organ
Sharing status 1A for heart transplantation. He was 6 ft 1 in and weighed 150 pounds. His blood type was O؉. Assessment for prior allosensitization was performed and revealed no circulating antibodies against HLA antigens. Hemodynamics stabilized and the end-organ function improved with IABP support and intravenous dopamine. Efforts to wean IABP support failed. After remaining on these therapies for 3 weeks, he had several episodes of sustained ventricular tachycardia requiring cardioversion and the addition of amiodarone. Systemic hypotension ensued that was refractory to advancing treatment, and there was rapid clinical deterioration. The decision was made to proceed with MCS as a bridge to transplantation (BTT). A HeartMate II LV assist device (LVAD) was inserted without complications, and the patient made a steady recovery. He was discharged to home 2 weeks postoperatively.
Dr Milano: MCS devices are increasingly being used as temporary support for patients awaiting cardiac transplanta-tion. These devices are typically implanted in patients who have failed pharmacological therapies and support with IABP or other percutaneously implanted assist devices. Without this option, such patients would surely not survive to cardiac transplantation. The choice of MCS device depends on the length of support required and the need for isolated left or biventricular support. This patient's hemodynamics demonstrate preserved RV function and an absence of pulmonary arterial hypertension. The RV stroke work index [(mean pulmonary artery pressureϪmean central venous pressure)ϫ stroke volume/body surface area] can be used as an objective measure of RV performance. Patients with an RV stroke work index of Ͻ300 mm ⅐ mL Ϫ 1 ⅐ m Ϫ2 have a particularly high risk of RV failure after isolated LVAD implant. A central venous pressure-to-PCWP ratio Ͼ0.65 is associated with a higher risk of perioperative RV failure. In this patient, the RV stroke work index and central venous pressure-to-PCWP ratio was not predictive of post-LVAD RV failure. 24 Therefore, as was done in this case, it is appropriate to use a durable LVAD as a BTT. It is also important to consider the burden of ventricular arrhythmia when selecting a MCS device. Ventricular arrhythmias after LVAD implantation can lead to progressive RV failure and inefficient LVAD function owing to impaired filling of the device. Because ventricular arrhythmias were not a primary manifestation of this patient's HF until he was in critical shock and being supported with multiple agents with arrhythmogenic potential, LVAD implantation was considered the best treatment option.
This patient fits the profile of an increasing number of those who would not have survived without a BTT LVAD. Although no randomized trials have compared medical therapy (including inotropic agents) with BTT LVADs, multiple retrospective studies have demonstrated improved survival with LVAD support. The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) trial randomized a population of patients with New York Heart Association class IV HF who were ineligible for transplantation to receive either pulsatile LVAD or optimal medical therapy. Patients treated with an LVAD experienced a 48% mortality reduction and improved quality of life. 25 Although available data support the superiority of LVAD therapy over medical therapy in patients with end-stage HF, there is limited information to guide the use of device therapy in less sick patients. The low operative risk associated with earlier implantation suggests that patients who are candidates for transplantation should be considered for LVAD therapy before their condition deteriorates. In this patient, characteristics such as his size and blood type that are predictive of longer wait times might have triggered this discussion before the advent of refractory cardiogenic shock. Dr Rogers: Because of the anticoagulation/antiplatelet requirements for patients treated with contemporary LVADs, patients with treated with these devices must be managed carefully to balance the risks of thrombosis and bleeding. Continuous-flow devices are associated with the development of acquired von Willebrand disease and an increased incidence of mucosal arteriovenous malformations. 26 In combination, these 2 phenomena can lead to an increased risk of bleeding that is not readily amenable to therapy. 26 In cases such as this, the general approach is to modify anticoagulants/ antiplatelet therapy and to perform endoscopy with the hope of finding lesions that can be treated with thermoablation. If bleeding persists, it is appropriate to revisit urgent cardiac transplantation as a rescue therapy from BTT support. Current United Network for Organ Sharing allocation policy allows VAD patients to have an automatic 30-day status 1A listing, with timing at the discretion of the center. Because there is a risk of allosensitization resulting from repeated blood transfusion, retesting for anti-HLA antibodies must be performed if this patient is to continue to be listed for transplantation.
Discussion
Patients with refractory end-stage HF (American Heart Association stage D) from severe ventricular systolic dysfunction typically experience gradual clinical decline and repeated recurrence of symptoms despite optimal medical therapy. Such patients characteristically have symptoms at rest or with minimal exertion, cannot perform most activities of daily living, and commonly require repeated and prolonged hospitalizations for intensive management. When patients progress to this advanced stage, they are faced with a limited number of therapeutic options and 1-year mortality rates approaching 50%. 1 Concurrently, improved early survival of patients with acute coronary syndromes and less severe HF has resulted in an increasing number of patients who develop stage D HF and thus require advanced HF therapies. Although difficult to quantify, it is currently estimated that Ͼ100 000 patients meet an indication for heart transplantation. 27 Although transplantation offers an effective therapy, its application is limited by the lack of sufficient donor organs and strict eligibility criteria. Over the last 2 decades, for example, roughly 2000 heart transplantations were performed annually in North America, far below the number of patients in need of this therapy. 28, 29 About 10% of patients listed for transplan-tation die each year, and many more deteriorate, making transplantation a higher-risk endeavor. Fortunately, the last decade has seen remarkable advances in the field of MCS devices, specifically implantable VADs, that provide alternatives to patients needing heart transplantation (as a bridge to decision or BTT).
Accurately assessing patient prognosis is a critical aspect of the HF evaluation. Several univariate predictors of survival have been identified, including New York Heart Association functional class, presence of coronary artery disease, poor ventricular function, low mean arterial pressure, impaired hemodynamic and laboratory parameters, low peak V O 2 , and persistent elevation of neurohormones. 27 The predictive value of a low peak V O 2 is emphasized by its use to select both transplantation and VAD candidates. 30 The aforementioned variables can be entered into prognostic models such as the Enhanced Feedback for Effective Cardiac Treatment Score, Heart Failure Survival Score, and the Seattle Heart Failure Model to estimate patient risk. 31, 32 In patients with severe HF, these models have modest prognostic abilities and can overestimate survival free of VAD or urgent transplantation. 6, 7 Therefore, risk stratification in these patients requires careful consideration of many variables that are linked to prognosis, with careful attention paid to variables that are not included in global risk models but significantly affect life expectancy.
Typically, patients who qualify for cardiac transplantation have a predicted average life expectancy of Ͻ1 year and meet specific indications that have been identified to minimize the risk of allograft failure, complications related to the cardiac transplant operation, and adverse outcomes associated with chronic immunosuppression (Table 1) . 27 Although patients generally have substantial symptom burden, they can vary considerably in their preference for comfort and improved quality of life over efforts directed at prolonging survival. 23, 33 Before proceeding with evaluation for transplantation, patients and their families must acknowledge the risks and benefits of advanced therapies and incorporate their goals of care into medical decision making. Once a patient is deemed a suitable candidate, the recipient selection process and the donor allocation systems are subject to rigorous standards. Patients undergo an extensive medical and psychosocial evaluation to detect contraindications to transplantation, to evaluate the urgency of transplantation, and to gauge immunologic status. Patients undergo immunologic evaluation to determine ABO blood type, degree of allosensitization by panel reactive antibody testing, and identification of specific HLA targets. The most common cause of allosensitization is pregnancy; however, sensitization can occur with blood transfusions, previous transplantation, or insertion of a VAD. Listed patients are assigned a risk status (Table 2) .
Because merely listing patients for heart transplantation is not a therapeutic intervention, LVADs are increasingly being used in the management of pretransplantation patients. In general, VADs are classified according to their flow characteristics and evolving mechanisms used to augment cardiac output, as well as the implant location, length of ventricular support required, and the ventricle(s) supported (Table 3) . 24, 34 Short-term VADs can be used in critically ill patients as a bridge to recovery or until a decision is made regarding eligibility for more long-lasting cardiac replacement therapies. For patients awaiting transplantation, durable LVADs can improve survival and quality of life. 35 Contemporary LVADs have been developed that are mechanically reliable, are sized to include smaller patients, and are therefore emerging as a more effective strategy for BTT. Whereas heart transplantation eligibility criteria are fairly well defined, candidate selection for LVAD placement as a BTT is an evolving field, likely as a result of rapid improvements in technology and experience with these devices. Important insights about the appropriate use of LVAD therapy have been gleaned from the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), a National Institutes of Health-funded registry that classifies VAD recipients into 7 risk profiles based primarily on hemodynamic data ranging from cardiogenic shock to stable ambulatory HF (Table  2) . Currently, the vast majority of patients implanted with a VAD are in the highest-risk groups (INTERMACS level 1 or 2). 36, 37 These patients are in critical cardiogenic shock, and waiting for a donor organ with continued medical therapy or a percutaneous support device (ie, IABP) is usually not an option because of clinical instability. Although short-or long-term MCS is often the last remaining option for survival in INTERMACS 1 and 2 patients, progressive end-organ dysfunction, debilitation, altered mental status, and need for emergent surgery negatively affect survival after MCS. This observation has catalyzed a realization that device implantation before the advent of critical illness may be more favorable. Implicit in this approach is the consideration of LVAD therapy in lieu of, or before, initiation of inotropic support in patients awaiting transplant (INTERMACS level 3 and 4). MCS has been shown to provide an excellent survival benefit at this stage of HF, as demonstrated in the analysis of registry and trial data. 27, 38 The optimal timing for LVAD implantation is not well defined, and the risks and benefits of long-term inotropic support along with contemporary HF therapies must be weighed against those of an LVAD. Although newer-generation LVADs are an attractive therapy for patients awaiting transplantation, considerable perioperative and postoperative risks remain, including those that can affect transplantation candidacy and outcomes such as the development of allosensitization, infection, bleeding, stroke, and the need for a repeat sternotomy at the time of transplantation.
Contemporary selection of patients for LVAD therapy relies heavily on a combination of measures of clinical status, inotrope dependence, and invasive hemodynamic parameters, with the caveat that many of these are relative and institution specific (Table 4) . 36 Several predictors of poor outcomes after LVAD implantation have been identified, including age, female sex, diabetes mellitus, RV function, prior cardiac surgery, preexisting right-sided HF, respiratory failure, sepsis, mechanical ventilation, renal dysfunction, and coagulopathy. RV failure after isolated LVAD is a major complication and accounts for much of the short-term morbidity and mortality. As was done in this case, assessment of RV function with imaging, hemodynamic, and laboratory data is an important step in early risk stratification to define the suitability of isolated left-sided support. RV failure risk scores have been constructed that attempt to identify patients who are at a high risk for postimplantation RV failure and may require biventricular assist device or total artificial heart support. Several global risk scores have been developed that use readily accessible clinical variables to provide some guidance about short-term mortality; however, they are all based on first-generation devices and have not been prospectively validated in newer devices. 36, 37 
Conclusions
The approach toward a patient considered to have refractory end-stage HF (AHA stage D HF) should begin with confirmation of the diagnosis and identification of contributing conditions. Physical examination, laboratory testing, multimodality imaging, and cardiopulmonary exercise testing can provide crucial objective data on the patient's clinical status. Patients with true refractory HF commonly have rapid clinical deterioration and may require inotropic agents to augment cardiac performance. Invasive hemodynamic testing remains useful for establishing diagnosis, for selecting therapeutic agents, and for determining immediate candidacy for transplantation. Finally, although cardiac transplantation currently offers the most effective treatment for end-stage HF, its widespread use is limited by the number of organs available and strict eligibility criteria. The last decade has seen significant developments in the field of MCS for both short-term and long-term ventricular support. Newer-generation LVADs are currently available that can provide adequate support for many years and restore a high quality of life while patients await cardiac transplantation.
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